The global pathogen reduction systems market is expected to grow at a CAGR of 19.8% during the forecast period of 2025-2034, driven by the rising incidence of bloodborne diseases, advancements in pathogen reduction systems, and increasing focus on patient safety across the globe.
Pathogen reduction systems help in reducing or eliminating pathogens like viruses, bacteria, and fungi, from blood products and other biological materials. They help ensure the safety of blood transfusions, tissue transplants, and plasma-derived products by reducing the risk of transmitting infectious diseases. Chemical agents, such as psoralens or riboflavin (vitamin B2), are widely used as pathogen reduction systems. These chemicals get activated by light and bind to the genetic material of pathogens which prevents them from replicating and causing infection. Ultraviolet or UV light is another method used to inactivate pathogens by damaging their nucleic acids. Further, filtration method such as nanofiltration is also used to physically remove pathogens based on size.
According to the World Health Organisation (WHO), 40% of the 118.5 million blood donations collected globally are reported in high-income countries. The blood donation rate based on samples of 1000 individuals is estimated to be 31.5 donations in high-income countries and 16.4 donations in upper-middle-income countries. The increase in the volume of blood donation and transfusion is driving the growth of the pathogen reduction systems market. Further, as the need for blood and blood products continues to grow as a result of factors such as an aging population, rising chronic disease burden, and an increase in the number of medical procedures, the market demand for pathogen reduction systems is poised to surge in the coming years.
One of the significant market trends is the rising technological advancements in pathogen reduction systems which have improved the efficacy and safety of these methods, further propelling their demand. The development of next-generation pathogen reduction technologies is anticipated to elevate the market value. Moreover, the introduction of stricter guidelines and regulations for blood safety and the prevention of transfusion-transmitted infections by the government and regulatory bodies is likely to drive the adoption of pathogen reduction systems in healthcare facilities.
The market also benefits from the expansion of blood banks and transfusion services which contributes to the demand for effective pathogen reduction technologies to ensure the safety of blood products. Additionally, heightened awareness among healthcare professionals and the general public about the risks associated with transfusion-transmitted infections is also bolstering the market demand.
Top 5 Companies Leading the Global Pathogen Reduction Systems Market in 2025
1. Terumo BCT, Inc.
| Headquarters |
Lakewood, Colorado |
| Establishment |
1964 |
| Website |
terumobct.com |
Terumo Blood and Cell Technologies is a prominent player in the market, known for its products and services in apheresis collections, pathogen reduction, and manual and automated whole blood processing. It was originally established as COBE Laboratories in 1964 and has a solid market presence in over 130 countries. Terumo BCT's Mirasol® Pathogen Reduction Technology (PRT) System is one of its key products which uses riboflavin and UV light to reduce pathogens in platelets and plasma. Mirasol PRT not only reduces the pathogen load of disease-causing bacteria, viruses, and parasites but also inactivates the residual white blood cells that may cause transfusion reactions in patients.
2. Macopharma SA
| Headquarters |
Mouvaux, France |
| Establishment |
1977 |
| Website |
https://www.macopharma.com/ |
France-based Macopharma SA is a significant player in the medical devices market in the blood sector. The company is focused on developing next-generation pathogen reduction technologies to enhance the safety of blood products. THERAFLEX UV-Platelets system is one of the advanced pathogen reduction technologies developed by the company that employs UV-C light to inactivate pathogens in platelet concentrates. Macopharma is also working towards expanding its product offerings to address the rising demand for pathogen reduction systems, especially in regions experiencing a high burden of infectious diseases.
3. Cerus Corporation
| Headquarters |
California, United States |
| Establishment |
1991 |
| Website |
https://www.cerus.com |
Headquartered in Concord, California, Cerus Corporation is one of the major players in the market, known for developing and supplying advanced technologies and pathogen-protected blood components to hospitals and patients. The company leverages strategic partnerships and regulatory approvals to propel the adoption of pathogen-reduction technologies in new markets. Cerus Corporation 's flagship product is the INTERCEPT® Blood System, which is designed to use amotosalen and UV light to inactivate pathogens in platelets, plasma, and red blood cells. The company claims that this pathogen reduction technology has been used at over 100 blood centers globally, with proven pathogen protection against a broad range of bacteria, enveloped and non-enveloped viruses, protozoa, and leukocytes.
4. AngioDynamics, Inc.
| Headquarters |
New York, United States |
| Establishment |
1988 |
| Website |
angiodynamics.com |
United States-based AngioDynamics is a medical technology company that significantly contributes to the pathogen reduction systems market growth. The company is investing in research and development to develop innovative solutions that can be used to optimize the safety of blood products and other medical therapies. AngioDynamics, Inc. is focused on integrating pathogen reduction technologies into its existing product lines to reduce the risk of infections and complications in various medical procedures.
5. Octapharma AG
| Headquarters |
Lachen, Switzerland |
| Establishment |
1983 |
| Website |
https://www.octapharma.com |
Octapharma, headquartered in Lachen, Switzerland, ranks as one of the largest human protein manufacturers in the world. The company is widely known for developing and producing human proteins from human cell lines and human plasma. To enhance the safety and efficacy of its products, the company heavily invests in improving its pathogen reduction technologies to ensure the highest standards of product safety. Octapharma has a market presence in 118 countries, with 7 R&D sites and 5 manufacturing plants. The company also boasts over 190 plasma donation centers across the United States and Europe.
Share